GlassScriptPhysician profile
Zachary Goodwin Keenum
NPI 1639605223
$2,121.71
in general payments reported to CMS, 2019-2025
14 companies · $620 in 2025
The $620 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $223 · 2022: $76.64 · 2023: $723 · 2024: $479 · 2025: $620.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,518 · Travel and Lodging: $304.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,518.16 |
| Travel and Lodging | $303.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $971.02 | 2021-2025 | Clareon, Argos, Centurion |
| Glaukos Corporation | $272.47 | 2024-2025 | Idose, Idosetr |
| Bausch & Lomb Americas INC. | $151.87 | 2023-2025 | Stellaris, Xiidra |
| Genentech USA, INC. | $138.05 | 2021 | |
| Revance Therapeutics, INC. | $100.00 | 2025 | Daxxify |
| Horizon Therapeutics Plc | $93.55 | 2022-2023 | Tepezza |
| Abbvie INC. | $79.85 | 2025 | |
| Oyster Point Pharma, INC. | $68.81 | 2023-2024 | Tyrvaya |
| Amgen INC. | $66.27 | 2024 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $61.24 | 2025 | Xdemvy |
| Ocular Therapeutix, INC. | $53.10 | 2024 | Dextenza |
| Dompe US, INC. | $43.46 | 2025 | Oxervate |
| Harrow Eye, LLC | $22.02 | 2025 | Vevye |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zachary Keenum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.